SCHEMBL6327592

SCHEMBL6327592

O=C1CCC(Cc2ccc(F)cc2F)CN1c1c(Cl)cccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.44
HTR2C P28335 5/20 0.44
MAPK14 Q16539 4/20 0.39
P2RX7 Q99572 8/20 0.39
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
BACE1 P56817 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
PGR P06401 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6337245 1.00 HTR2A (0.44) HTR2AHTR2CMAPK14P2RX7BCHE
SCHEMBL6335030 1.00 HTR2A (0.44) HTR2AHTR2CMAPK14P2RX7BCHE
SCHEMBL6329598 0.90 HTR2A (0.39) HTR2AHTR2CP2RX7BCHEACHE
SCHEMBL6328298 0.89 HTR2A (0.39) HTR2AHTR2CMAPK14P2RX7PGR
SCHEMBL6335486 0.87 EED (0.43) P2RX7CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL6329615 0.87 P2RX7 (0.37) HTR2AHTR2CP2RX7BCHEACHE
SCHEMBL6328644 0.87 HTR2A (0.37) HTR2AHTR2CMAPK14P2RX7PGR
SCHEMBL6330114 0.86 P2RX7 (0.43) HTR2AHTR2CMAPK14P2RX7BCHE
SCHEMBL6336004 0.86 P2RX7 (0.39) HTR2AHTR2CP2RX7BCHEACHE
SCHEMBL6331063 0.86 PGR (0.41) HTR2AHTR2CMAPK14P2RX7PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO. LTD. (JP) 2005-04-21 US claimed
EP-1447401-A1 PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-08-18 EP claimed
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO. LTD. (JP) 2005-04-21 US disclosed
EP-1447401-A1 PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085509-A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient MAPKAP1, MAPK1, MAPK8 HTR2A 2694/4885HTR2C 3759/4885MAPK14 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.